Secukinumab showed superior efficacy over etanercept in clearing skin, according to pivotal Novartis Phase III psoriasis results presented at EADV

Novartis has nnounced the results from the head-to-head Phase III FIXTURE study showing secukinumab (AIN457), an interleukin-17A (IL-17A) inhibitor, showed superior efficacy to etanercept in moderate-to-severe plaque psoriasis1. Etanercept is a NICE-approved anti-tumour necrosis factor (anti-TNF) therapy, used to treat moderate-to-severe plaque psoriasis2. These significant results are being presented today at the 22nd Congress of the European Association of Dermatology and Venereology (EADV) in Istanbul, Turkey1. Secukinumab is the first psoriasis treatment that selectively targets IL-17A to present Phase III results. The pivotal FIXTURE study met all primary and pre-specified key secondary endpoints1. Both doses of secukinumab showed improved efficacy…
View More/Source Article